{"id":"W2783829013","doi":"10.1016/j.jaad.2018.01.017","title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":329,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sanofi Genzyme; LEO Pharma; Dermira; Vanda Pharmaceuticals; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Roivant Sciences; Celgene; Genentech; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Pfizer; King's College London; Galderma; Eli Lilly and Company","keywords":"Medicine; Eczema Area and Severity Index; Placebo; Atopic dermatitis; Adverse effect; Randomized controlled trial; Clinical endpoint; Internal medicine; Placebo-controlled study; Gastroenterology; Dermatology; Double blind; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001983601,0.001121633,0.001955495,0.0002507401,0.0003181782,0.0008091863,0.0006341055,0.001561145,0.003679187],"category_scores_gemma":[0.001353565,0.0004838117,0.00138518,0.0001878101,0.0007029236,0.0007370232,0.0002424667,0.001802655,0.0006141031],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004549162,"about_ca_system_score_gemma":0.0006839908,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004468119,"about_ca_topic_score_gemma":0.001054443,"domain_scores_codex":[0.9995547,0.0002288804,0.0000351737,0.00008699764,0.00003882913,0.00005539598],"domain_scores_gemma":[0.999299,0.0002198786,0.0001864488,0.00004105661,0.00005540204,0.0001982009],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.955107,0.009296738,0.002182627,0.0008672593,0.0008044624,0.00008753751,0.00007373022,0.0002602953,0.00894435,0.00006207144,0.0008737588,0.02144019],"study_design_scores_gemma":[0.9077929,0.0872997,0.003332571,0.00003047097,0.0002924299,0.00006939655,0.00001596213,0.0002905127,0.0004552965,0.0000364315,0.000376294,0.000008074933],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906676,0.005329572,0.0003233099,0.0004237006,0.0002307271,0.001593215,0.0004955586,0.00006187283,0.000874389],"genre_scores_gemma":[0.9915542,0.002386381,0.0009976497,0.0009096161,0.0003728832,0.001709602,0.0007116729,0.00001399606,0.001343932],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003679187,"threshold_uncertainty_score":0.01230812,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009610947437418426,"score_gpt":0.3044593541179478,"score_spread":0.2948484066805294,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}